![\"Book](\"https:\/\/www.newsbeep.com\/ca\/wp-content\/uploads\/2026\/01\/\/2c0f5d91-3e85-4d73-99f5-c0a9e33a77d9.jpg\")
<\/p>\nThe signs have been there for a while. Take, for instance, a meeting organised by Nestl\u00e9 executives in the winter of 2024. There in the Alps the multinational\u2019s top team discussed a new line of products. These products were, Aimee Donnellan explains in Off the Scales, engineered to deal with a very specific, very new and very worrying threat: the growing chunk of consumers for whom the once-reliable trifecta of sugar, fat and salt no longer appealed.<\/p>\n
Or you could point to the letter a UK fund sent a little later to investors after dropping all its alcohol stocks. The fund too had heard ill tidings: it feared alcoholism might not be the bankable investment it once had been. It thought addiction could soon have an effective treatment.<\/p>\n
<\/p>\n
This was probably also about the time that in your own office you started noticing the people with the oddly gaunt expression, and the new wardrobe.<\/p>\n
But if that didn\u2019t tip you off to what was going on, there was the US Centers for Disease Control and Prevention and its 2024 National Health and Nutrition Examination Survey. In the middle of this regular publication, without fanfare, was what could well be the most important table in modern public health. It was the table outlining how fat the country was.<\/p>\n
The US was \u2014 spoiler alert \u2014 still extremely fat. More than four in ten people were obese. But what was important was that that number of fat people was just a little bit lower than it had been. For decades the western waistline had been increasing \u2014 flabbily, inexorably, unstoppably. Now it had stopped. For the first time in a generation the national belt needed tightening rather than expanding. Why?<\/p>\n
Well, you know the answer, just as you know the secret behind your colleagues\u2019 svelter but saggier faces. Eight years ago a new medication for diabetes appeared. It worked pretty well and did pretty well. It was marketed in the US using a song. The chorus was: \u201cOh, oh, oh, Ozempic.\u201d<\/p>\n
\u2022 Tim Spector: Weight-loss jabs are fine\u2026 if we stop eating junk<\/a><\/p>\n The most significant bit of that advert wasn\u2019t the song, though. It was actually the bit that most people barely noticed: the bit where they listed the side-effects. One of those side-effects was \u201cweight loss\u201d. For the benefit of the regulator as much as patients there was also a warning. On the screen stern letters read: this is not a weight loss drug. But it was.<\/p>\n As Donnellan, a columnist for Reuters, outlines in her meticulously reported account, the inventors of Ozempic always realised that the \u201cside-effect\u201d would really be the main effect. Diabetes was just the start for the class of drugs known as GLP-1 agonists. The target was the biggest disease of all: obesity. And the rewards were \u2014 still are \u2014 vast. In 2023, unlike much of Europe, Denmark\u2019s economy grew. The reason was almost entirely that Novo Nordisk, which makes Ozempic<\/a>, is based in Denmark.<\/p>\n What will the world look like when fat drugs can be taken as pills rather than injections, when the (unwanted) side-effects are minimised and, perhaps most significantly of all, when the drugs are off patent?<\/p>\n We don\u2019t know the answers. We don\u2019t, as Donnellan makes clear, even completely know what these drugs do. We know they interfere with a hormonal mechanism to suppress appetite. There is evidence that they might not just deal with food cravings, but alcohol cravings too \u2014 hence the move away from drinks company investments.<\/p>\n To give a sense of the range of conditions being investigated as potential benefits, there is some evidence that they might aid everything from getting pregnant to preventing Alzheimer\u2019s.<\/p>\n \u2022 Ozempic side-effects: what weight-loss drugs do to your body<\/a><\/p>\n Donnellan is not the first to write a book about what this means. What she adds, though, is a reporter\u2019s eye. She takes us to the conferences where pharmaceutical companies face off. She takes us to the labs where star scientists retrospectively battle it out over patents and credit.<\/p>\n She takes us inside the boardrooms where European executives suppress their squeamishness about advertising medication to Americans using a catchy jingle \u2014 and get rewarded for their boldness\/unprincipledness (delete as appropriate) with soaring stock prices. She takes us to the dinners and deals where pharma reps woo doctors over arugula and eggplant salads.<\/p>\n There is the good and the bad. She takes us to the women who had spent their lives loathing their bodies and now find they can move freely \u2014 physically and in society. Then she unflinchingly describes some of the more unpleasant rare side-effects. Such as the woman whose gut essentially stopped working. Food just got stuck, with very smelly results.<\/p>\n She also talks about the problem highlighted by a report this week<\/a> that if you come off them, the weight piles back on. To the concern of public health officials, and the delight of pharmaceutical investors, these may well be drugs for life.<\/p>\n You can tell Donnellan is a journalist. The book is reported non-fiction, and it is done very well \u2014 briskly and brightly and with lots of shoe leather. It is also the sort of book where you tend to meet interviewees alongside brief precis of an arbitrarily chosen body part. One man is tall and brawny. Another has soft brown eyes that crease at the edges. One scientist will learn on reading the book that \u2014 perhaps to her surprise \u2014 she has \u201cdarting blue eyes that appear to be always scanning and observing\u201d.<\/p>\n